SPS
CRL icon

Susquehanna Portfolio Strategies’s Charles River Laboratories CRL Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,600
Closed -$2.87M – 572
2024
Q1 		$2.87M Sell
10,600
-2,200
-17% -$525K 0.07% 283
2023
Q4 		$3.03M Buy
+12,800
New +$2.52M 0.05% 355

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Susquehanna Portfolio Strategies's CRL Position: Q2 2024 in Review

Susquehanna Portfolio Strategies sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 10,600 shares — an estimated $2.87M sold.

Susquehanna Portfolio Strategies first reported a position in CRL in Q4 2023 and held it in 2 quarters. The position peaked at $3.03M in Q4 2023. 664 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Susquehanna Portfolio Strategies reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 10,600 Charles River Laboratories shares in Q2 2024, an estimated $2.87M.
  • Susquehanna Portfolio Strategies first reported a position in Charles River Laboratories in Q4 2023 and held it in 2 quarters.
  • Susquehanna Portfolio Strategies's Charles River Laboratories position peaked at $3.03M in Q4 2023.
  • 664 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2024, filed 15 Aug 2024.